These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39017806)

  • 1. Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.
    Matsubara N; Miura Y; Nishiyama H; Taoka R; Kojima T; Shimizu N; Hwang J; Ote T; Oyama R; Toyoizumi K; Mukhopadhyay S; Triantos S; Deprince K; Loriot Y
    Int J Clin Oncol; 2024 Oct; 29(10):1516-1527. PubMed ID: 39017806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
    Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
    Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Loriot Y; Matsubara N; Park SH; Huddart RA; Burgess EF; Houede N; Banek S; Guadalupi V; Ku JH; Valderrama BP; Tran B; Triantos S; Kean Y; Akapame S; Deprince K; Mukhopadhyay S; Stone NL; Siefker-Radtke AO;
    N Engl J Med; 2023 Nov; 389(21):1961-1971. PubMed ID: 37870920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
    Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
    Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
    Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
    J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
    Loriot Y; Necchi A; Park SH; Garcia-Donas J; Huddart R; Burgess E; Fleming M; Rezazadeh A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Zhong B; Stuyckens K; Santiago-Walker A; De Porre P; O'Hagan A; Avadhani A; Siefker-Radtke AO;
    N Engl J Med; 2019 Jul; 381(4):338-348. PubMed ID: 31340094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.
    Yamamoto N; Kuboki Y; Harano K; Koyama T; Kondo S; Hagiwara A; Suzuki N; Fujikawa E; Toyoizumi K; Mukai M; Doi T
    Invest New Drugs; 2024 Aug; 42(4):376-385. PubMed ID: 38833067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma.
    Van Sanden S; Youssef A; Baculea S; Stubbs K; Triantos S; Yuan Z; Daly C
    J Health Econ Outcomes Res; 2024; 11(2):49-57. PubMed ID: 39267886
    [No Abstract]   [Full Text] [Related]  

  • 10. Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
    Dosne AG; Valade E; Goeyvaerts N; De Porre P; Avadhani A; O'Hagan A; Li LY; Ouellet D; Perez Ruixo JJ
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):151-164. PubMed ID: 34977972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial.
    Park JO; Feng YH; Su WC; Oh DY; Keam B; Shen L; Kim SW; Liu X; Liao H; Qing M; Zhang C; Qian J; Tang X; Li P; Triantos S; Sweiti H
    BMC Cancer; 2024 Aug; 24(1):1006. PubMed ID: 39138436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].
    Casuscelli J; von Amsberg G; Retz M
    Urologie; 2024 Oct; 63(10):1002-1010. PubMed ID: 39235511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
    Roubal K; Myint ZW; Kolesar JM
    Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Erdafitinib in Patients With Tumors With
    Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erdafitinib to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Tilgener C; Bedke J
    Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
    [No Abstract]   [Full Text] [Related]  

  • 17. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
    Matsubara N; Yonese J; Kojima T; Azuma H; Matsumoto H; Powles T; Rosenberg JE; Petrylak DP; Matsangou M; Wu C; Campbell M; Yamashiro M
    Cancer Med; 2023 Feb; 12(3):2761-2771. PubMed ID: 36052536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.